Hypertrophic cardiomyopathy (HCM) is an umbrella term for a heterogeneous heart muscle
disease that was historically (and still is) defined by the detection of left ventricular
(LV) hypertrophy (LVH) in the absence of abnormal cardiac loading conditions. Long
after this morphological definition was established, the genetic basis of HCM was
discovered, and we now know it is predominantly caused by autosomal dominant mutations
in sarcomeric protein genes.1 Several patterns of LVH have been described in HCM:
asymmetric septal (here referred to as “classic” HCM), concentric, reverse septal,
neutral, and apical (ApHCM),2 as well as other, rarer LVH variants such as isolated
lateral LVH and isolated inferoseptal LVH. Distinguishing between morphological HCM
subtypes has conferred little in terms of personalized management strategies, with
one distinctive exception: ApHCM. Compared with classic HCM, ApHCM is more sporadic,
sarcomere mutations are detected less frequently, there is more atrial fibrillation
(AF) and sudden cardiac death (SCD) risk factors differ. No authoritative ApHCM‐specific
recommendations to guide diagnosis, family screening, and patient risk stratification
currently exist.
First described in Japan in 1976,2 ApHCM is exemplified by “giant” negative precordial
T‐waves on electrocardiography and by “spadelike” configuration of its LV cavity in
end diastole.3 This review summarizes the epidemiology, clinical expression, genetics,
and prognosis of ApHCM, while also highlighting knowledge gaps.
Pathophysiology and Clinical Characteristics
Epidemiology
ApHCM is not as rare as first thought, accounting for up to 25% of HCM in Asian populations
and 1% to 10% in non‐Asians.4 Ethnic variation influences prevalence, natural history,
and prognosis, and Western sufferers may exhibit a more malignant form.1
Genetics
Fewer ApHCM patients report a positive family history compared with classic HCM,5
potentially suggesting differences in ascertainment screening and/or different etiological
(genetic, environmental) factors. In this context, the applicability of conventional
HCM risk stratification can be challenged given that family history of SCD is heavily
weighted6, 7 (Table 1).1, 2, 4, 8, 9, 10, 11
Table 1
Genetic and Phenotypic Differences and Similarities Between Classic HCM and ApHCM
Classic (ASH) HCM
ApHCM
% Of all HCM cases
462
82
Mean age at diagnosis, y
46 (all subtypes)
41.41
ECG
Voltage criteria for LVH
Nonspecific ST‐segment and T‐wave abnormalities
Deep, narrow Q‐waves in the lateral and inferior leads
Giant negative T‐waves characteristic
Voltage criteria for LVH, T‐wave inversion
AF relatively common; NSVT
Genetics
Autosomal dominant sarcomere protein gene mutations
Identifiable pathogenic gene mutations in 34%–40%
Majority of gene mutations in MYBPC3 and MYH7
Autosomal dominant sarcomere protein gene mutations
Identifiable pathogenic gene mutations in 13%–25%
Majority of gene mutations in MYBPC3 and MYH711
Associated morbidity
Atrial fibrillation8
LVOTO
Diastolic dysfunction
Chest pain
Pulmonary hypertension9
Ventricular arrhythmias
Atrial fibrillation
Diastolic dysfunction
Chest pain
Pulmonary hypertension
Ventricular arrhythmias
All‐cause mortality rate
1.3% (all subgroups combined)10
0.5%–4% (but much lower patient numbers)—likely equivalent4
ApHCM indicates apical hypertrophic cardiomyopathy; ASH, asymmetrical septal hypertrophy;
HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; LVOTO, left ventricular
outflow tract obstruction; MYBPC3, myosin‐binding protein C; MYH7, β‐myosin heavy
chain; NSVT, nonsustained ventricular tachycardia.
John Wiley & Sons, Ltd
In terms of identifiable sarcomere gene mutations, one study that used a 9‐gene panel,
25% of 71 ApHCM versus 34% of 1053 all‐cause HCM patients had detectable genetic defects11:
ACTC1 (cardiac α‐actin 1), MYBPC3 (myosin‐binding protein C), MYH7 (β‐myosin heavy
chain), MYL2 (myosin regulatory light chain), MYL3 (myosin essential light chain),
TNNT2 (cardiac troponin T2), TNNI3 (cardiac troponin I3), TNNC1 (troponin C1, slow
skeletal and cardiac type), and TPM1 (α‐tropomyosin 1). The phenotype and clinical
outcomes of these ApHCM patients did not differ between genotype‐positive or ‐negative
subjects.11 Other studies confirm reduced mutation rates in ApHCM versus all‐cause
HCM (13% versus 40% with an 8‐gene panel, plus 3 metabolic cardiomyopathy genes: GLA
(α‐galactosidase A) for Fabry disease; LAMP2 (lysosomal associated membrane protein‐2)
for Danon disease; and PRKAG2 (protein kinase, AMP‐activated, noncatalytic, gamma‐2)
for PRKAG2 cardiomyopathy.12
As with classic HCM, identified genetic mutations in ApHCM are mainly sarcomeric,
autosomal dominant, and influenced by environmental and ethnic/demographic factors
including sex.5 Specific data regarding genetic profiling in the different ApHCM morphologies
or ethnicities are lacking. In a study looking at genotype‐phenotype correlations
in ApHCM, those that carried a pathogenic sarcomere gene mutation had a stronger family
history of HCM (39% versus 26%; P=0.4) but no phenotypic features were not significantly
different.11 European Society of Cardiology (ESC) and American College of Cardiology
Foundation/American Heart Association HCM guidelines provide no ApHCM‐specific genotyping
or family screening recommendations.
Histopathology
Myocardial biopsies from the LV apex in ApHCM have been compared with those from the
septum in classic HCM and show less myocyte disorganization (10% versus 86%, P<0.0001),13
although severity and extent of interstitial fibrosis was equivalent (100% versus
93%; P=ns).13
Diagnostic Criteria and Subtypes
Characterized by lack of apical tapering and the presence of precordial T‐wave inversion,
the diagnostic criteria for ApHCM have evolved over time; originally contingent on
left ventriculography demonstrating “unique spade‐like configuration and marked apical
obliteration” together with electrocardiographic “giant” negative T‐waves and high
QRS voltage.14 With imaging advances, definition now relies on demonstrating LVH predominating
in the LV apex, with wall thickness in the apex ≥15 mm and a ratio of maximal apical
to posterior wall thickness ≥1.5, based on echocardiography or cardiovascular magnetic
resonance (CMR).1 Of note, this diagnostic criterion was not included in the 2014
ESC HCM guideline. The American Heart Association also lacks specific diagnostic criteria
for ApHCM and similarly uses wall thickness of ≥15 mm as their threshold for diagnosis
of HCM; however, a recent study assessing the reliability of sudden cardiac death
recommendations used diagnostic criteria as unexplained hypertrophy in a nondilated
LV with wall thickness ≥13 mm by CMR or transthoracic echocardiography,10 highlighting
an emerging trend toward using a lower diagnostic cutoff.
In ApHCM, there is typically no LV outflow tract obstruction from systolic anterior
motion of the anterior mitral valve leaflet and therefore no associated mitral regurgitation.
ApHCM can exist with or without midventricular obstruction and cavity obliteration
(MVOCO) and with or without apical aneurysm formation.15 It can be subclassified into
3 forms: (1) “pure,” with isolated apical hypertrophy; (2) “mixed,” with both apical
and septal hypertrophy16 but with the apex thickest1; and (3) “relative” ApHCM, believed
to be an early ApHCM phenotype. Individuals with relative ApHCM do not meet conventional
diagnostic criteria for ApHCM but share imaging findings with the pure group. Relative
ApHCM is diagnosed when electrocardiography shows characteristic precordial T‐wave
inversion and CMR shows loss of the usual apical wall thickness tapering due to apical
wall thickness exceeding basal wall thickness, although failing to reach the ApHCM
diagnostic cutoff of wall thickness ≥15 mm.17 As the normal heart exhibits tapering
of wall thickness towards the apex, loss of this is abnormal. One CMR study reported
22 subjects, 95% of whom had additional cardiac structural abnormalities including
left atrial (LA) dilatation, apical aneurysm, myocardial scar, and ≥20 mm apical systolic
cavity obliteration.17 In another study, relative apical hypertrophy appeared to be
the only explanation for giant T‐wave inversion, given the absence of other causes
of this abnormality.18
Relative ApHCM was originally considered entirely benign, but recent data suggest
associated pathology with LA dilatation, apical aneurysm, and myocardial scar17 (Figure 1).
Relative ApHCM may simply represent early disease that with time progresses to overt
ApHCM, eventually meeting conventional criteria, as with other HCM variants where
penetrance is age dependent.
Figure 1
ECG and CMR in relative ApHCM. A, ECG demonstrates precordial T‐wave inversion and
voltage criteria for LVH. B, Two‐chamber CMR demonstrates loss of apical tapering
with relative but not absolute apical hypertrophy in diastole (Bi), systolic apical
cavity obliteration (Bii) and LGE in the hypertrophied apex (Biii). ApHCM indicates
apical hypertrophic cardiomyopathy; CMR, cardiovascular magnetic resonance; LGE, late
gadolinium enhancement; LVH, left ventricular hypertrophy.
Natural History and Prognosis
ApHCM is more prevalent in men than women, with male‐to‐female ratios typically 1.6
to 2.8:1.1, 4 The average age at presentation is 41.4±14.5 years,1 with mixed ApHCM
tending to be more symptomatic and have a greater likelihood of LA enlargement, increased
LV filling pressures, and elevated blood cardiac protein biomarkers in the absence
of acute coronary syndrome.1
ApHCM was originally thought to carry no increased mortality risk,1 but recent data
suggest annual cardiac death rates of 0.5% to 4%, approaching those for classic HCM.4,
11 Increased mortality in women was reported, possibly due to more AF and pulmonary
hypertension4 (Table 1). Patients with mixed ApHCM, younger age at presentation (<41 years),1
complete end‐systolic cavity obliteration at the level of the papillary muscles, paradoxical
diastolic flow jet by echocardiography, and apical asynergy16 have been shown to have
higher cardiovascular morbidity. Malignant ventricular arrhythmias and mortality has
been linked to apical aneurysms, but only in Western sufferers.16
In terms of small‐vessel disease and microvascular obstruction, a feature recognized
in HCM, there may be an increased role for ischemia in ApHCM from cavity obliteration
and the persistence of apical contraction into early‐mid diastole, resulting in dynamic
small‐vessel obstruction in the apical segments, regional myocardial perfusion defects,
and chest pain.19 Impaired myocyte relaxation and increased energetic cost of early
hypercontractility may contribute, particularly in early disease.
Electrocardiography and Arrhythmias
Giant negative T‐waves defined as negative voltage of ≥1 mV (≥10 mm)1 are characteristic
but not mandatory for diagnosis (Figure 2). In one ApHCM study of 105 patients, 94%
had abnormal ECGs with voltage criteria for LVH (65%) and T‐wave inversion (93%),
but only 47% had giant negative T‐waves.1 Maximal T‐wave negativity weakly correlated
with apical wall thickness, and electrocardiography does not well differentiate mixed
and pure ApHCM variants.1 Giant negative T‐waves have also been identified in other
types of HCM and cardiac disease, including coronary artery disease, so are not a
pathognomonic feature.
Figure 2
EKG in pure ApHCM. Voltage criteria for LVH and giant negative T‐wave inversion in
precordial and inferolateral leads. ApHCM indicates apical hypertrophic cardiomyopathy;
LVH, left ventricular hypertrophy.
Holter monitoring in ApHCM detected asymptomatic and symptomatic nonsustained ventricular
tachycardia (VT) in 18% and 5%, respectively1; AF in 12%; VT in 3%; and VF in 1%.1
AF prevalence in other studies was higher, at 20% to 28%.3 Monomorphic VT occurs in
ApHCM with aneurysms, possibly related to reentry around the aneurysm. LA enlargement
secondary to LV diastolic dysfunction at the time of first ApHCM presentation predicts
later AF,20 which is commoner in females and prognostically adverse.4, 20
Serum Biomarkers
Comparing high‐sensitivity cardiac troponin T levels between different HCM morphological
subtypes found rates in ApHCM versus nonobstructive versus obstructive classical HCM
of 14%, 47%, and 57%, respectively.21 High‐sensitivity cardiac troponin T correlated
with age, LA area, and maximum LV wall thickness when considering all subtypes.21
In another study, cardiac troponin I was significantly lower in ApHCM compared with
classic HCM, and it correlated with maximum LV wall thickness, LV dysfunction, and
male sex when considering all subtypes.22
Cavity Obliteration
Apical systolic cavity obliteration occurs in pure, and to a lesser extent, relative
ApHCM. A measure of the degree of apical cavity obliteration is provided by the ratio
of the end‐systolic length of apical obliteration to the end‐systolic length of the
LV cavity.23 A systolic obliteration‐to‐cavity ratio >0.5 is associated with increased
incidence of AF, stroke, heart failure, and cardiovascular death.24 Degree of obliteration
rather than apical wall thickness influences prognosis.23
MVOCO may occur as a consequence of midapical lateral and septal hypertrophy15 and
therefore a complication of mixed rather than pure ApHCM. In severe cases, midventricular
cavity obliteration persists in diastole and is often associated with a paradoxical
midcavity diastolic flow jet, which indicates the associated presence of an apical
aneurysm.16 In contrast, the pathophysiology behind midventricular obstruction in
classic HCM is attributable to the basal‐to‐midseptal hypertrophy coming into contact
with a hypercontractile but nonhypertrophied LV free wall, often with the interposition
of hypertrophied papillary muscle.
Apical Aneurysms
Apical aneurysms are defined as a discrete, thin‐walled, dyskinetic/akinetic segment
of the most distal portion of the LV with a relatively wide communication to the main
cavity in diastole.16 They occur in 2% of patients with HCM and 13% to 15% with ApHCM16,
25 (Figure 3). A cue to their presence is the persistence of apical blood pooling
distal to the point of apical systolic cavity obliteration17 and/or a paradoxical
diastolic jet. Small aneurysms are often overlooked on echocardiography and may be
difficult to delineate without advanced imaging.15 In ApHCM, it is hypothesized that
apical aneurysms and obstructive physiology arise from regional myocardial scarring
caused by repeatedly exposing the apical myocardium to increased LV wall stress and
high systolic pressures, leading to pressure overload, increased oxygen demand, impaired
coronary perfusion, and ischemia.25 The dyskinetic/akinetic aneurysm confers risk
of apical thrombus formation and thromboembolic stroke.25 Apical aneurysms have been
associated with LVH severity, SCD, monomorphic VT,24 LV systolic dysfunction, and
heart failure.25
Figure 3
CMR comparison of mixed ApHCM (A through C) and pure ApHCM (D through F), both with
apical aneurysm formation. Long‐axis views of a patient with mixed ApHCM in diastole
in 2‐chamber (Ai) and 4‐chamber (Aii), which in systole demonstrate midventricular
obstruction but not total cavity obliteration due to persistence of apical chamber
(Bi; Bii). The apical aneurysm contains LGE (Ci; Cii). A different patient with pure
ApHCM has a thinned aneurysmal apex demonstrated in diastole on 2‐ (Di) and 4‐chamber
views (Dii). In systole, the apical aneurysm becomes apparent (Ei; Eii) and contains
LGE (Fi; Fii). ApHCM indicates apical hypertrophic cardiomyopathy; LGE, late gadolinium
enhancement.
It is important to distinguish apical aneurysms arising from ApHCM from those arising
from midcavity obstruction in classic HCM. One study investigating outcomes in patients
with apical aneurysms irrespective of the HCM morphological subtype, identified aneurysms
in 4.8%.26 Authors identified 2 distinct patterns of LVH in those with aneurysms:
segmental thickening confined to the distal LV in 51%, and in the remaining 49% diffuse
thickening of the septum and free wall, resulting in an “hourglass” configuration
with midventricular muscular narrowing, creating discrete proximal and distal chambers.26
Thromboembolic events were 2‐fold more common (P=0.06) in those with apical aneurysms
compared with those without, and this subgroup also experienced a 3‐fold greater adverse
event rate, at 6.4%/year.
Phenotypic Mimics
Fabry disease causes progressive LVH that potentially mimics ApHCM. Up to 23% of patients
with Fabry disease with LVH have ApHCM pattern by CMR.27
Long‐term athletic training produces cardiac structural changes, namely, increased
diastolic dimensions of the LV cavity, LVH, and increased LV mass.28 In athletes with
LVH, distinguishing the physiological “athlete's heart” from HCM may be challenging.
An overlapping “gray zone” is described when absolute LV wall thickness is between
13 and 15 mm, observed in 2% of highly trained male athletes.29 Highly trained female
athletes rarely show >11 mm of LVH, suggesting that athletic females presenting within
the “gray zone” are more likely to have HCM.29 In one athletes study exploring LVH
≥13 mm on echocardiography, 3 had pure apical LVH (range 15–18 mm), and 2 had LVH
basally, as well as in the apex.28 Native T1 and extracellular volume values using
CMR are lower in athletes than in HCM, which is a useful differentiator.30 Furthermore,
as LVH increases in athletes, extracellular volume continues to decrease, whereas
in HCM it continues to increase.
Athletes with pure apical LVH had normal ECGs (no T‐wave inversion28), and the phenotype
was postulated to reflect athletic training, rather than true HCM. Another study demonstrated
that athletes with HCM were 3 times likelier to exhibit ApHCM than their sedentary
HCM counterparts (35.8% versus 11.9%).31 It is difficult to distinguish apical LVH
attributable to athletic remodeling from ApHCM; however, an ApHCM‐pattern ECG is regarded
as unequivocally abnormal.31 The increased frequency of ApHCM in athletes may itself
reflect an ascertainment bias resulting from screening programs, but as mentioned
above, the difficulty in assessing SCD risk remains.
Imaging
Echocardiography
Transthoracic echocardiography can reveal apical hypertrophy, differentiate between
pure and mixed forms, and identify additional prognostic features that could influence
outcome such as the presence of diastolic dysfunction, MVOCO, or apical aneurysms.23,
32, 33 However, imaging the apex remains a potential challenge, particularly for subtle
prognostic features such as apical akinesis or sequestration caused by massive hypertrophy.16
Early phenotypes and relative ApHCM could be missed by echocardiography; thus, those
with deep T‐wave inversion and noncontributory echocardiography should undergo additional
imaging.34
Although global LV systolic function may appear normal or supranormal in ApHCM, LV
peak systolic mitral annular velocity (S’) is commonly reduced, more so in the mixed
rather than in the pure form.32 Interstitial fibrosis of the subendocardium (where
muscle bundles aligned along the LV driving long‐axis function), commonly seen in
ApHCM, may partly account for this impairment. Furthermore, end‐systolic MVOCO and
paradoxical diastolic flow jets predict apical asynergy and apical aneurysms, and
are associated with increased morbidity16 (Figure 4).
Figure 4
Transthoracic echocardiography in ApHCM. ApHCM with a small discrete apical chamber
visible in the apical 3‐chamber view (A) and corresponding polar plot showing loss
of longitudinal strain apically (B). At rest, continuous wave Doppler across the point
of distal ventricular obstruction demonstrates a midsystolic peaking jet, followed
by a drop in velocity prior to second peak representing paradoxical early diastolic
jet flow, with gradients of 54 and 39 mm Hg, respectively (Ci). During Valsalva, systolic
and diastolic jets merge, with a systolic intracavity gradient of 127 mm Hg, and a
lengthening of the diastolic “tail” toward late diastole (Cii). By contrast, (D) demonstrates
continuous wave Doppler traces from a patient with ApHCM and midcavity obstruction.
At rest, there is midsystolic loss of Doppler alignment due to cavity obliteration,
with corresponding Doppler dropout before paradoxical diastolic jet (Di). During Valsalva,
the measured systolic gradient is unchanged, but the paradoxical diastolic jet gradient
now exceeds 100 mm Hg with extension in duration to the end of diastole (Dii). ApHCM
indicates apical hypertrophic cardiomyopathy.
Two‐dimensional strain or speckle tracking demonstrate regional apical dyskinesis
and reduced LV “twist,” which can be attributable to cavity obliteration negating
the effect of apical twist in systolic contraction.
Cardiovascular Magnetic Resonance
CMR may detect early ApHCM phenotypes better than echocardiography. Apical hypertrophy
was missed by echocardiography in 40% of cases, later detected by CMR.35 CMR is more
sensitive at detecting apical aneurysms and can identify 25% to 43% of those missed
by echocardiography.25, 36 CMR has advantages in confounding patient populations,
such as athletes. Late gadolinium enhancement (LGE) is common in HCM; the presence
and amount of LGE may be associated with the severity of hypertrophy as well as increased
risk of heart failure and SCD.37 LGE patterns in ApHCM are characteristically apical
and subendocardial37, 38, 39–patterns that are uncommon in other HCM variants in the
absence of coexisting coronary disease. This “MI pattern” of LGE adds credence to
the hypothesis that apical myocardial ischemia is key in ApHCM. HCM registry data
showed LGE in ApHCM in 45.8% of subjects.40 Aneurysms are considered the arrhythmogenic
substrate, but it may be the intra‐aneurysm scar that matters most. Of note, extent/presence
of (apical or any) LGE does not feature in the ESC HCM risk‐stratification algorithm.
Despite heterogeneity in reported native T1 values (indicating diffuse myocardial
fibrosis) in classic and ApHCM versus healthy controls, values consistently correlate
with wall thickness and LGE and can also be elevated in LGE‐negative apical segments.41
Areas of T2 elevation (indicating myocardial edema) are also seen in HCM.
Rest and stress perfusion data are missing for ApHCM (Figure 5). Rest perfusion abnormalities
have been well described in classic HCM, correlating with severity of LGE, degree
of hypertrophy and myocardial fibrosis.42 The clinical significance of perfusion abnormalities
is not yet explored.
Figure 5
Quantitative perfusion mapping in ApHCM. CMR pixelwise inline perfusion maps at rest
(A), stress (B) in (i) basal, (ii) mid, (iii) apical short axis and (iv) 2‐chamber
views in a patient with ApHCM and MVOCO. Stress perfusion defects are seen in the
hypertrophied apex. Bull's‐eye plots are shown (rest C, stress D). There is 37% MBF
reduction at stress (D) apically (1.47 mL/g per minute) vs 2.35 mL/g per minute in
remote, non‐hypertrophied segments. Rest MBF(C) is 0.74 and 0.85 mL/g per minute,
respectively. MPR is 1.99 in the apex and 2.76 in remote myocardium, indicating microvascular
disease in the hypertrophied apex. Healthy volunteer stress MBF is 2 to 4 mL/g per
minute. ApHCM indicates apical hypertrophic cardiomyopathy; CMR, cardiovascular magnetic
resonance; MBF, myocardial blood flow; MPR, myocardial perfusion reserve; MVOCO, midventricular
obstruction and cavity obliteration.
Cardiac Computerized Tomography
Computerized tomography (CT) using iodine‐based contrast detects late enhancement
consistent with the presence of myocardial fibrosis. While the segment‐based sensitivity
of computerized tomography for HCM fibrosis detection is lower than for CMR, patient‐based
sensitivity is similar43 offering a viable alternative for those unable to undergo
CMR. As it is not uncommon for ApHCM to open clinically with chest pain and T‐wave
inversion, computerized tomography reporters should be alert to the possibility of
discovering ApHCM in such referrals.
Nuclear Scintigraphy
Perfusion imaging using single photon emission computed tomography (SPECT) unveils
the characteristic (but not pathognomonic) “solar polar” perfusion map of ApHCM: an
intensely bright apical spot of counts surrounded by a circumferential ring of decreasing
counts.44 Other findings include increased apical tracer uptake at rest and the spadelike
configuration of the LV.45 Fixed and reversible stress perfusion defects are reported
in the context of unobstructed epicardial coronary arteries,45 but again, the significance
of these findings is unexplored. Single photon emission computed tomography can miss
ApHCM because dense apical fibrosis normalizes apical tracer counts so single photon
emission computed tomography and other findings (ECG, wall thickness) do not correlate.1,
45
Angiography
Left ventriculography identifies the characteristic “ace of spades” LV cavity configuration
in end diastole in 69% of cases1 and aids the detection of apical aneurysms.16
Management Strategies
Management in HCM involves symptom assessment and determination of likely mechanisms
of symptoms, risk assessment and its mitigation, family screening, and chronic symptom/risk
management. Treatment options for ApHCM are based on classic HCM approaches aiming
to minimize any heart failure, AF, or MVOCO symptoms and reduce/mitigate ventricular
arrhythmias and sudden death. Therapy is medical or electrophysiological (device/ablation),
but as LV outflow tract obstruction is typically absent in ApHCM, therapeutic benefits
may be lower than in classic HCM, and myectomy‐type approaches are exploratory rather
than routine (Table 2).
Table 2
Management Differences and Similarities Between Classic HCM and ApHCM
Classical (ASH) HCM
ApHCM
Medical
β‐Blockers–first line treatment (aim to reduce LVOTO and burden of ventricular arrhythmias)
Nondihydropyridine calcium channel blockers–second line
Atrial fibrillation and thromboembolism less common than in ApHCM but if present,
anticoagulant indicated
β‐blockers also first line (symptom improvement in MVOCO and reduce burden of ventricular
arrhythmias)
Nondihydropyridine calcium channel blockers also second line
Anticoagulants in the case of atrial fibrillation or thromboembolism
Ablation
Alcohol septal ablation of hypertrophied basal septum in symptomatic LVOTO
VT ablation considered
Potential role of alcohol ablation in symptomatic ApHCM with MVOCO (no randomized
control data)
No role for alcohol septal ablation
VT ablation in rare cases
Devices
ICD implantation (ESC 5‐y HCM SCD risk score tailored more specifically to ASH risk
factors than other morphological variants)
AHA guidance on ICD implantation broader
ICDs may be underutilized because of current scoring criteria if using ESC algorithm
Current prospective trial of distal ventricular pacing for ApHCM with drug refractory
symptoms and MVOCO
Surgical
Septal myectomy (reduces symptoms and risks associated with LVOTO)
Few case reports detailing symptomatic improvement following apical myectomy. No randomized
control data
AHA indicates American Heart Association; ApHCM, apical hypertrophic cardiomyopathy;
ESC, European Society of Cardiology; ICD, implantable cardiac defibrillator; LVOTO,
left ventricular outflow tract obstruction; MVOCO, midventricular obstruction and
cavity obliteration; SCD, sudden cardiac death; VT, ventricular tachycardia.
John Wiley & Sons, Ltd
Medical
β‐Blockers reduce rest and exercise‐induced LV outflow tract obstruction in classic
HCM,46 and the negative inotropic and chronotropic effects of nondihydropiridine calcium
channel blockers prolong LV filling, reduce gradients, and improve subendocardial
blood flow in classic HCM,46 but data for ApHCM are missing.
Catheter Ablation
Although sustained monomorphic VT is uncommon in classic HCM, a case series reported
monomorphic VT in ApHCM from reentry in a region of apical scar. Circuits were varied
(endocardial, epicardial, intramural) and successfully ablated using endocardial/epicardial/transcoronary
approaches.47
Devices
There are currently no trials or predictive models to guide implantable cardiac defibrillator
(ICD) insertion specifically for ApHCM. The ESC 5‐year HCM SCD risk score6, 7 was
based on all HCM morphological subtypes without breakdown for ApHCM.6 Potential risk
markers for SCD in ApHCM (apical aneurysm, MVOCO, midcavity gradient, paradoxical
diastolic flow jet) were not shortlisted predictors. ApHCM patients tend to score
negative for family history of SCD, and there is concern that risk may be underestimated.
For intermediate‐risk patients, the ESC guideline suggests that the presence of “other”
potentially relevant associated adverse markers like apical aneurysms (alluding to
ApHCM) may also be taken into account when planning implantable cardiac defibrillators.48
In contrast, Maron's group have recently sought to evolve the American Heart Association
guidance for implanting cardiac defibrillators by proposing new criteria for HCM patients
fulfilling one or more major risk factors for SCD. These include novel high‐risk markers
such as CMR LGE demonstration of extensive fibrosis comprising ≥15% of LV mass by
quantification or “extensive and diffuse” by visual estimation, and also the presence
of LV apical aneurysm, independent of size, with associated regional scarring.10 This
risk stratification is more sensitive at predicting those at risk of SCD than the
ESC guidance10, 40 and demonstrates progression toward understanding more individualized
risk factors.
Dual‐chamber pacing with short atrioventricular delay has been proposed as a treatment
for symptomatic HCM with apical LVH where there are detectable midapical LV obstructive
gradients.49 This is thought to work by reducing the extent of regional LV cavity
obliteration through the introduction of contractile dyssynchrony. Our group is currently
conducting a randomized placebo‐controlled trial of distal ventricular pacing in patients
with drug‐refractory symptoms and MVOCO (http://Clinicaltrials.gov NCT03450252).
Alcohol Septal Ablation and Apical Myectomy
The absence of overt septal hypertrophy causing LV outflow tract obstruction may render
septal ablation/myectomy in ApHCM unwarranted, but single case studies have highlighted
a potential role in those with symptomatic MVOCO, as it may reduce gradients and improve
heart failure symptoms. Additionally, apical myectomy has been reported to increase
end‐diastolic dimensions and improve symptoms.
Conclusions
ApHCM poses specific etiological, diagnostic, prognostic, and therapeutic challenges
compared with more commonly detected and better understood morphological HCM variants.
The phenotypic spectrum and natural history of ApHCM (“pure,” “mixed,” and “relative”)
is being clarified, as is the impact of sarcomere gene mutations, sex, and other clinical
and environmental factors on phenotype expression. Further research is needed to understand
why some patients develop mixed ApHCM with a higher risk of arrhythmias, heart failure,
and SCD, while others go on to manifest the pure form with a relatively more benign
course. ApHCM‐specific treatments are needed to halt or regress the LV mid‐to‐apical
hypertrophy and its ensuing complications and multicenter longitudinal outcome data
needed to robustly inform on an SCD risk stratification tool appropriate for ApHCM.
Sources of Funding
Dr Hughes is supported by the British Heart Foundation (grant number FS/17/82/33222).
Dr Captur and Professor Moon are supported by the Barts Charity HeartOME1000 grant
MGU0427. Dr Captur is supported by the National Institute for Health Research Rare
Diseases Translational Research Collaboration (NIHR RD‐TRC, #171603) and by NIHR University
College London Hospitals Biomedical Research Center. Professor Moon is directly and
indirectly supported by the University College London Hospitals NIHR Biomedical Research
Center and Biomedical Research Unit at Barts Hospital, respectively.
Disclosures
None.